Essentials for Clinicians: Thoracic Tumours - Editors and Contributors

Editors

Rolf A. Stahel
Laboratory of Molecular Oncology, Clinic and Policlinic for Oncology, University Hospital Zurich, Zurich, Switzerland

Solange Peters
Department of Oncology, University of Lausanne, Lausanne, Switzerland

Marina Chiara Garassino
Thoracic Oncology Unit, Department of Medical Oncology, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

Series editor: Michele Ghielmini
Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

Contributors

Chapter 1 - Epidemiology, Pathogenesis, and Risk Factors

E Capelletto, Department of Oncology, University of Turin, AOU San Luigi-Orbassano, Orbassano, Italy

S Novello, Department of Oncology, University of Turin, AOU San Luigi-Orbassano, Orbassano, Italy

Chapter 2 - Prevention and Screening of Lung Cancer

G Veronesi, Lung Cancer Early Detection Unit, Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy

Chapter 3 - Diagnosing Lung Cancer

C Dooms, University Hospitals Leuven, Respiratory Division, Leuven, Belgium

Chapter 4 - Histopathological and Molecular Characterisation of Lung Cancer

A Warth, Institute for Pathology, University Hospital Heidelberg, Heidelberg, Germany

Chapter 5 - Principles of Surgery of Non-Small-Cell Lung Cancer

MA Hoda, Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna, Austria

W Klepetko, Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna, Austria

Chapter 6 - Principles of Radiotherapy of Thoracic Tumour

S Senan, Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands

Chapter 7 - Adjuvant and Neoadjuvant Therapy

B Besse, Department of Cancer Medicine, Gustave Roussy, Villejuif, France

Chapter 8 - Treatment of Metastatic Non-Small-Cell Lung Cancer

N Reinmuth, Department of Thoracic Oncology, LungenClinic, Grosshansdorf, Germany; Member of the German Center for Lung Research (DZL), Germany

M Reck, Department of Thoracic Oncology, LungenClinic, Grosshansdorf, Germany; Member of the German Center for Lung Research (DZL), Germany

Chapter 9 - Treatment of Small-Cell Lung Cancer: Chemotherapy and Radiotherapy

D De Ruysscher, University Hospitals Leuven/KU Leuven, Leuven, Belgium

Chapter 10 - Malignant Pleural Mesothelioma

GL Ceresoli, Thoracic and GU Oncology Unit, Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy

G Pasello, Thoracic Oncology Unit, Medical Oncology II, Istituto Oncologico Veneto, Padova, Italy

F Calabrese, Department of Cardiothoracic and Vascular Sciences, University of Padova Medical School, Padova, Italy

Chapter 11 - Thymic Malignancies

N Girard, Université Claude Bernard Lyon 1, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France

Chapter 12 - Neuroendocrine Tumours of Lung Origin

MC Garassino, Thoracic Oncology Unit, Department of Medical Oncology, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

A Billè, Thoracic Surgery Unit, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

S Pusceddu, Medical Oncology Unit, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

Chapter 13 - Emerging Targets and New Agents in Lung Cancer

TA Yap, Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK

SB Popat, Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK

Disclosures

B Besse: no conflict of interest

A Billè: no conflict of interest

F Calabrese: no conflict of interest

E Capelletto: no conflict of interest

GL Ceresoli: no conflict of interest

D De Ruysscher: no conflict of interest

C Dooms: no conflict of interest

MC Garassino: no conflict of interest

N Girard: no conflict of interest

MA Hoda: no conflict of interest

W Klepetko: no conflict of interest

S Novello: no conflict of interest

G Pasello: no conflict of interest

SB Popat: Uncompensated consultant to: AstraZeneca, Roche, Boehringer-Ingelheim, Lilly, Pfizer, GlaxoSmithKline, Pierre Fabre; Research funding: Pierre Fabre, Roche, Boehringer-Ingelheim

S Pusceddu: no conflict of interest

M Reck: Consultant to Hoffmann-La Roche, Lilly, Bristol-Myers Squibb, Novartis, Boehringer-Ingelheim, Pfizer, AstraZeneca; Speaker honoraria from Hoffmann-La Roche, Lilly, Bristol-Myers Squibb, Novartis, Boehringer-Ingelheim, Pfizer, AstraZeneca

N Reinmuth: Consultant to Hoffmann-La Roche, Lilly, Amgen, Bristol-Myers Squibb; Speaker honoraria from Hoffmann-La Roche, Lilly, Novartis, Boehringer-Ingelheim, Otsuka, Bristol-Myers Squibb

S Senan: has received speakers’ honoraria from Varian Medical Systems, and is also a member of the Trial Management Group for a phase III study in lung cancer sponsored by Lilly Oncology

G Veronesi: no conflict of interest

A Warth: no conflict of interest TA Yap: no conflict of interest

« Previous Page

Last update: 14 August 2012